{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:06:07Z","timestamp":1773277567057,"version":"3.50.1"},"reference-count":45,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            <jats:named-content content-type=\"genus-species\">Bacillus anthracis<\/jats:named-content>\n            is the causative agent of anthrax, and its spores have been developed into lethal bioweapons. To mitigate an onslaught from airborne anthrax spores that are maliciously disseminated, it is of paramount importance to develop a rapid-response anthrax vaccine that can be mass administered by nonmedical personnel during a crisis. We report here that intranasal instillation of a nonreplicating adenovirus vector encoding\n            <jats:named-content content-type=\"genus-species\">B. anthracis<\/jats:named-content>\n            protective antigen could confer rapid and sustained protection against inhalation anthrax in mice in a single-dose regimen in the presence of preexisting adenovirus immunity. The potency of the vaccine was greatly enhanced when codons of the antigen gene were optimized to match the tRNA pool found in human cells. In addition, an adenovirus vector encoding lethal factor can confer partial protection against inhalation anthrax and might be coadministered with a protective antigen-based vaccine.\n          <\/jats:p>","DOI":"10.1128\/cvi.00280-12","type":"journal-article","created":{"date-parts":[[2012,10,25]],"date-time":"2012-10-25T04:20:53Z","timestamp":1351138853000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":25,"title":["An Adenovirus-Vectored Nasal Vaccine Confers Rapid and Sustained Protection against Anthrax in a Single-Dose Regimen"],"prefix":"10.1128","volume":"20","author":[{"given":"Jianfeng","family":"Zhang","sequence":"first","affiliation":[{"name":"Vaxin, Inc., Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Jex","sequence":"additional","affiliation":[{"name":"Vaxin, Inc., Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsungwei","family":"Feng","sequence":"additional","affiliation":[{"name":"Vaxin, Inc., Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria S.","family":"Sivko","sequence":"additional","affiliation":[{"name":"Battelle Biomedical Research Center, West Jefferson, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie W.","family":"Baillie","sequence":"additional","affiliation":[{"name":"Biological Defense Research Directorate, Naval Medical Research Center, Rockville, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley","family":"Goldman","sequence":"additional","affiliation":[{"name":"Biological Defense Research Directorate, Naval Medical Research Center, Rockville, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kent R.","family":"Van Kampen","sequence":"additional","affiliation":[{"name":"Vaxin, Inc., Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De-chu C.","family":"Tang","sequence":"additional","affiliation":[{"name":"Vaxin, Inc., Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"806","DOI":"10.4161\/hv.9777","article-title":"Is new always better than old?: the development of human vaccines for anthrax","volume":"5","author":"Baillie LW","year":"2009","unstructured":"BaillieLW. 2009. Is new always better than old?: the development of human vaccines for anthrax. Hum. Vaccin. 5:806\u2013812.","journal-title":"Hum. Vaccin."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.17.2236"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.49.2.291-297.1985"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.mam.2009.07.003","article-title":"Cellular and systemic effects of anthrax lethal toxin and edema toxin","volume":"30","author":"Moayeri M","year":"2009","unstructured":"MoayeriM LepplaSH. 2009. Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol. Aspects Med. 30:439\u2013455.","journal-title":"Mol. Aspects Med."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.5.1239"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0022172400044272"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00063030-200519040-00003","article-title":"Anthrax vaccines: a development update","volume":"19","author":"Little S","year":"2005","unstructured":"LittleS. 2005. Anthrax vaccines: a development update. BioDrugs 19:233\u2013245.","journal-title":"BioDrugs"},{"key":"e_1_3_2_9_2","first-page":"1","article-title":"Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009","volume":"59","author":"Wright JG","year":"2010","unstructured":"WrightJG QuinnCP ShadomyS MessonnierN Centers for Disease Control andPrevention. 2010. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm. Rep. 59:1\u201330.","journal-title":"MMWR Recomm. Rep."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00021-4"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"8300","DOI":"10.1128\/JVI.00183-10","article-title":"Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways","volume":"84","author":"Langley WA","year":"2010","unstructured":"LangleyWA BradleyKC LiZN SmithME SchnellMJ SteinhauerDA. 2010. Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways. J. Virol. 84:8300\u20138307.","journal-title":"J. Virol."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.mt.6300034","article-title":"Adenovirus-based prime-boost immunization for rapid vaccination against anthrax","volume":"15","author":"McConnell MJ","year":"2007","unstructured":"McConnellMJ HannaPC ImperialeMJ. 2007. Adenovirus-based prime-boost immunization for rapid vaccination against anthrax. Mol. Ther. 15:203\u2013210.","journal-title":"Mol. Ther."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1128\/JVI.79.10.6516-6522.2005","article-title":"Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates","volume":"79","author":"Santra S","year":"2005","unstructured":"SantraS SeamanMS XuL BarouchDH LordCI LiftonMA GorgoneDA BeaudryKR SvehlaK WelcherB ChakrabartiBK HuangY YangZY MascolaJR NabelGJ LetvinNL. 2005. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J. Virol. 79:6512\u20136522.","journal-title":"J. Virol."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"11474","DOI":"10.1128\/JVI.75.23.11474-11482.2001","article-title":"Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines","volume":"75","author":"Shi Z","year":"2001","unstructured":"ShiZ ZengM YangG SiegelF CainLJ van KampenKR ElmetsCA TangDC. 2001. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J. Virol. 75:11474\u201311482.","journal-title":"J. Virol."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.vaccine.2004.07.043","article-title":"Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans","volume":"23","author":"Van Kampen KR","year":"2005","unstructured":"Van KampenKR ShiZ GaoP ZhangJ FosterKW ChenDT MarksD ElmetsCA TangDC. 2005. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23:1029\u20131036.","journal-title":"Vaccine"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)49569-0"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/j.1365-2958.1994.tb00500.x","article-title":"Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity","volume":"13","author":"Klimpel KR","year":"1994","unstructured":"KlimpelKR AroraN LepplaSH. 1994. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol. Microbiol. 13:1093\u20131100.","journal-title":"Mol. Microbiol."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1089\/hum.1998.9.13-1909","article-title":"New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses","volume":"9","author":"Fallaux FJ","year":"1998","unstructured":"FallauxFJ BoutA van der VeldeI van den WollenbergDJ HehirKM KeeganJ AugerC CramerSJ van OrmondtH van der EbAJ ValerioD HoebenRC. 1998. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9:1909\u20131917.","journal-title":"Hum. Gene Ther."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1586\/erv.09.1","article-title":"Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines","volume":"8","author":"Tang DC","year":"2009","unstructured":"TangDC ZhangJ ToroH ShiZ Van KampenKR. 2009. Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines. Expert Rev. Vaccines 8:469\u2013481.","journal-title":"Expert Rev. Vaccines"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/jps.20157","article-title":"Development of stable liquid formulations for adenovirus-based vaccines","volume":"93","author":"Evans RK","year":"2004","unstructured":"EvansRK NawrockiDK IsopiLA WilliamsDM CasimiroDR ChinS ChenM ZhuDM ShiverJW VolkinDB. 2004. Development of stable liquid formulations for adenovirus-based vaccines. J. Pharm. Sci. 93:2458\u20132475.","journal-title":"J. Pharm. Sci."},{"key":"e_1_3_2_21_2","first-page":"3607","article-title":"Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity. 2006. Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity","volume":"174","author":"Zhang J","year":"2006","unstructured":"ZhangJ ShiZ KongFK JexE HuangZ WattJM Van KampenKR TangDC. 2006. Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity. 2006. Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity. Infect Immun. 174:3607\u20133617.","journal-title":"Infect Immun."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1128\/IAI.69.7.4509-4515.2001","article-title":"Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein","volume":"69","author":"Price BM","year":"2001","unstructured":"PriceBM LinerAL ParkS LepplaSH MateczunA GallowayDR. 2001. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect. Immun. 69:4509\u20134515.","journal-title":"Infect. Immun."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1021\/bp070258u","article-title":"Establishment of higher passage PER.C6 cells for adenovirus manufacture","volume":"24","author":"Berdichevsky M","year":"2008","unstructured":"BerdichevskyM GentileMP HughesB MeisP PeltierJ BlumentalsI Auni\u0146sJ AltarasNE. 2008. Establishment of higher passage PER.C6 cells for adenovirus manufacture. Biotechnol. Prog. 24:158\u2013165.","journal-title":"Biotechnol. Prog."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.gt.3301527","article-title":"Development of formulations that enhance physical stability of viral vectors for gene therapy","volume":"8","author":"Croyle MA","year":"2001","unstructured":"CroyleMA ChengX WilsonJM. 2001. Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther. 8:1281\u20131290.","journal-title":"Gene Ther."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"19ra12","DOI":"10.1126\/scitranslmed.3000490","article-title":"Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass","volume":"2","author":"Alcock R","year":"2010","unstructured":"AlcockR CottinghamMG RollierCS FurzeJ De CostaSD HanlonM SpencerAJ HoneycuttJD WyllieDH GilbertSC BreguM HillAV. 2010. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci. Transl. Med. 2:19ra12.","journal-title":"Sci. Transl. Med"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.vetimm.2011.05.007","article-title":"Single dose adenovirus vectored vaccine induces a potent and long-lasting immune response against rabbit hemorrhagic disease virus after parenteral or mucosal administration","volume":"142","author":"Fern\u00e1ndez E","year":"2011","unstructured":"Fern\u00e1ndezE ToledoJR ChiongM ParraF Rodr\u00edguezE MonteroC M\u00e9ndezL CapucciL Farn\u00f3sO. 2011. Single dose adenovirus vectored vaccine induces a potent and long-lasting immune response against rabbit hemorrhagic disease virus after parenteral or mucosal administration. Vet. Immunol. Immunopathol. 142:179\u2013188.","journal-title":"Vet. Immunol. Immunopathol."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1099\/vir.0.82727-0","article-title":"Rapid and sustained CD4+ T-cell-independent immunity from adenovirus-encoded vaccine antigens","volume":"88","author":"Holst PJ","year":"2007","unstructured":"HolstPJ BartholdyC StryhnA ThomsenAR ChristensenJP. 2007. Rapid and sustained CD4+ T-cell-independent immunity from adenovirus-encoded vaccine antigens. J. Gen. Virol. 88:1708\u20131716.","journal-title":"J. Gen. Virol."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1016\/j.vaccine.2007.05.024","article-title":"Experimental immunization of cats with a recombinant rabies-canine adenovirus vaccine elicits a long-lasting neutralizing antibody response against rabies","volume":"25","author":"Hu RL","year":"2007","unstructured":"HuRL LiuY ZhangSF ZhangF FooksAR. 2007. Experimental immunization of cats with a recombinant rabies-canine adenovirus vaccine elicits a long-lasting neutralizing antibody response against rabies. Vaccine 25:5301\u20135307.","journal-title":"Vaccine"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1089\/104303403322542310","article-title":"Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen","volume":"14","author":"Tan Y","year":"2003","unstructured":"TanY HackettNR BoyerJL CrystalRG. 2003. Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen. Hum. Gene Ther. 14:1673\u20131682.","journal-title":"Hum. Gene Ther."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"7994","DOI":"10.4049\/jimmunol.178.12.7994","article-title":"Lung dendritic cells rapidly mediate anthrax spore entry through the pulmonary route","volume":"178","author":"Cleret A","year":"2007","unstructured":"CleretA Quesnel-HellmannA Vallon-EberhardA VerrierB JungS VidalD MathieuJ TournierJN. 2007. Lung dendritic cells rapidly mediate anthrax spore entry through the pulmonary route. J. Immunol. 178:7994\u20138001.","journal-title":"J. Immunol."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1371\/journal.ppat.0030076","article-title":"Primary involvement of pharynx and Peyer's patch in inhalational and intestinal anthrax","volume":"3","author":"Glomski IJ","year":"2007","unstructured":"GlomskiIJ Piris-GimenezA HuerreM MockM GoossensPL. 2007. Primary involvement of pharynx and Peyer's patch in inhalational and intestinal anthrax. PLoS Pathog. 3:e76. doi:10.1371\/journal.ppat.0030076.","journal-title":"PLoS Pathog."},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1462-5822.2007.01098.x","article-title":"Potential dissemination of Bacillus anthracis utilizing human lung epithelial cells","volume":"10","author":"Russell BH","year":"2008","unstructured":"RussellBH VasanR KeeneDR KoehlerTM XuY. 2008. Potential dissemination of Bacillus anthracis utilizing human lung epithelial cells. Cell Microbiol. 10:945\u2013957.","journal-title":"Cell Microbiol."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.4.2022-2028.2002"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4161\/hv.3.3.4011","article-title":"Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge","volume":"3","author":"Huang J","year":"2007","unstructured":"HuangJ MiksztaJA FerriterMS JiangG HarveyNG DyasB RoyCJ UlrichRG SullivanVJ. 2007. Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge. Hum. Vaccin. 3:90\u201393.","journal-title":"Hum. Vaccin."},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1086\/426865","article-title":"Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms","volume":"191","author":"Mikszta JA","year":"2005","unstructured":"MiksztaJA SullivanVJ DeanC WaterstonAM AlarconJB DekkerJP3rd BrittinghamJM HuangJ HwangCR FerriterM JiangG MarK SaikhKU StilesBG RoyCJ UlrichRG HarveyNG. 2005. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J. Infect. Dis. 191:278\u2013288.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"10078","DOI":"10.1128\/JVI.77.18.10078-10087.2003","article-title":"Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system","volume":"77","author":"Lemiale F","year":"2003","unstructured":"LemialeF KongWP Aky\u00fcrekLM LingX HuangY ChakrabartiBK EckhausM NabelGJ. 2003. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J. Virol. 77:10078\u201310087.","journal-title":"J. Virol."},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"6357","DOI":"10.4049\/jimmunol.173.10.6357","article-title":"Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis","volume":"173","author":"Wang J","year":"2004","unstructured":"WangJ ThorsonL StokesRW SantosuossoM HuygenK ZganiaczA HittM XingZ. 2004. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. 173:6357\u20136365.","journal-title":"J. Immunol."},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1128\/JVI.76.1.127-135.2002","article-title":"Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response","volume":"76","author":"Molinier-Frenkel V","year":"2002","unstructured":"Molinier-FrenkelV LengagneR GadenF HongSS ChoppinJ Gahery-S\u00e9gardH BoulangerP GuilletJG. 2002. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J. Virol. 76:127\u2013135.","journal-title":"J. Virol."},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"7020","DOI":"10.1016\/j.vaccine.2011.07.073","article-title":"Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine","volume":"29","author":"Jones FR","year":"2011","unstructured":"JonesFR GabitzschES XuY BalintJP BorisevichV SmithJ SmithJ PengBH WalkerA SalazarM PaesslerS. 2011. Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine. Vaccine 29:7020\u20137026.","journal-title":"Vaccine"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"S413","DOI":"10.1086\/520603","article-title":"Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice","volume":"2","author":"Patel A","year":"2007","unstructured":"PatelA ZhangY CroyleM TranK GrayM StrongJ FeldmannH WilsonJM KobingerGP. 2007. Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. J. Infect. Dis. 2:S413\u2013420.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"e3548","DOI":"10.1371\/journal.pone.0003548","article-title":"Nasal delivery of an adenovirus-based vaccine bypasses preexisting immunity to the vaccine carrier and improves the immune response in mice","volume":"3","author":"Croyle MA","year":"2008","unstructured":"CroyleMA PatelA TranKN GrayM ZhangY StrongJE FeldmannH KobingerGP. 2008. Nasal delivery of an adenovirus-based vaccine bypasses preexisting immunity to the vaccine carrier and improves the immune response in mice. PLoS One 3:e3548. doi:10.1371\/journal.pone.0003548.","journal-title":"PLoS One"},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/gt.2008.181","article-title":"An adenoviral vector-based mucosal vaccine is effective in protection against botulism","volume":"16","author":"Xu Q","year":"2009","unstructured":"XuQ PichicheroME SimpsonLL EliasM SmithLA ZengM. 2009. An adenoviral vector-based mucosal vaccine is effective in protection against botulism. Gene Ther. 16:367\u2013375.","journal-title":"Gene Ther."},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1128\/JVI.02372-07","article-title":"Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection","volume":"82","author":"Yu JR","year":"2008","unstructured":"YuJR KimS LeeJB ChangJ. 2008. Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J. Virol. 82:2350\u20132357.","journal-title":"J. Virol."},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"10925","DOI":"10.1073\/pnas.1834478100","article-title":"A dually active anthrax vaccine that confers protection against both bacilli and toxins","volume":"100","author":"Rhie GE","year":"2003","unstructured":"RhieGE RoehrlMH MourezM CollierRJ MekalanosJJ WangJY. 2003. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc. Natl. Acad. Sci. U. S. A. 100:10925\u201310930.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1016\/j.vaccine.2005.08.031","article-title":"DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components","volume":"24","author":"Hahn UK","year":"2006","unstructured":"HahnUK BoehmR BeyerW. 2006. DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components. Vaccine 24:4569\u20134571.","journal-title":"Vaccine"},{"key":"e_1_3_2_46_2","doi-asserted-by":"crossref","first-page":"13601","DOI":"10.1073\/pnas.0405557101","article-title":"A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores","volume":"101","author":"Hermanson G","year":"2004","unstructured":"HermansonG WhitlowV ParkerS TonskyK RusalovD FerrariM LalorP KomaiM MereR BellM BrennemanK MateczunA EvansT KaslowD GallowayD HobartP. 2004. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc. Natl. Acad. Sci. U. S. A. 101:13601\u201313606.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00280-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00280-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:48:27Z","timestamp":1627591707000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00280-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1128\/CVI.00280-12"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00280-12","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"2012-05-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-10-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-01-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}